Image courtesy of Volpara
February 2, 2015 — To help improve breast cancer screening for the 40 percent of American women with dense breasts, Volpara Solutions announced it has signed an agreement enabling GE Healthcare to distribute VolparaDensity, VolparaAnalytics and VolparaDoseRT.
Under the agreement, GE Healthcare customers will have the option to purchase from GE Healthcare Volpara Solutions’ innovative suite of quantitative breast imaging tools that enable personalized measurements of volumetric density, patient-specific dose, breast compression and other factors designed to provide critical insight for breast imaging quality and workflow.
To date, more than 4 million women have had their breast density analyzed, using VolparaDensity, which is in use at breast imaging centers worldwide to help radiologists objectively assess density from both digital mammography and tomosynthesis images and to help determine which women with dense breasts may benefit from additional screening, such as with the GE Invenia Automated Breast Ultrasound (ABUS).
VolparaAnalytics is a dashboard that produces configurable reports for management of quality assurance, resource utilization and breast imaging workflow. VolparaDose provides a standardized measurement of patient-specific dose with consistent dose results across mammography systems from different manufacturers.
GE Healthcare’s breast care solution is designed to address the needs of each unique woman: 3D breast tomosynthesis, automated breast ultrasound (ABUS), contrast-enhanced spectral mammography (CESM), molecular breast imaging (MBI), breast magnetic resonance imaging (MRI) and healthcare IT workflows.
“We know that screening using our automated breast ultrasound has a 37% relative increase in cancer detection overall than mammography alone in women with dense breasts,” said Jessie Jacob, M.D., MMM, chief medical officer of Breast Health at GE Healthcare.
For more information: www.volparasolutions.com, www.gehealthcare.com
April 16, 2024 
